

Resource Summary Report

Generated by [dkNET](#) on Sep 7, 2026

JVM-2

RRID:CVCL_1319

Type: Cell Line

Proper Citation

RRID:CVCL_1319

Cell Line Information

URL: https://web.expasy.org/cellosaurus/CVCL_1319

Proper Citation: RRID:CVCL_1319

Description: Cell line JVM-2 is a Transformed cell line with a species of origin Homo sapiens (Human)

Sex: Female

Disease: Mantle cell lymphoma

Defining Citation: [PMID:3093393](#), [PMID:3262465](#), [PMID:7849311](#), [PMID:16183118](#), [PMID:16448697](#), [PMID:16960149](#), [PMID:20164919](#), [PMID:20454443](#), [PMID:21746927](#), [PMID:22460905](#), [PMID:24362935](#), [PMID:25315077](#), [PMID:25688540](#), [PMID:25960936](#), [PMID:26589293](#), [PMID:27397505](#), [PMID:28196595](#), [PMID:30285677](#), [PMID:30629668](#), [PMID:30894373](#), [PMID:31068700](#), [PMID:31160637](#), [PMID:35839778](#)

Comments: Population: Caucasian., Part of: MD Anderson Cell Lines Project., Part of: Lymphoma Research Foundation Mantle Cell Lymphoma cell bank (LRF MCL cell bank)., Part of: LL-100 blood cancer cell line panel., Part of: COSMIC cell lines project., Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).

Category: Transformed cell line

Organism: Homo sapiens (Human)

Name: JVM-2

Synonyms: JVM2

Cross References: CLO:CLO_0007047, EFO:EFO_0005476, CLDB:cl2965, ArrayExpress:E-MTAB-783, ArrayExpress:E-MTAB-2770, ArrayExpress:E-MTAB-3610, ArrayExpress:E-MTAB-7721, ArrayExpress:E-MTAB-7722, ATCC:CRL-3002,

BioSample:SAMN03471706, BioSample:SAMN10988575, cancercellines:CVCL_1319, CCRID:4201HUM-CCTCC00302, CCTCC:GDC0302, Cell_Model_Passport:SIDM01013, ChEMBL-Cells:ChEMBL3308530, ChEMBL-Targets:ChEMBL2366359, Cosmic:907269, Cosmic:2088017, Cosmic:2296995, Cosmic:2756234, Cosmic-CLP:907269, DepMap:ACH-000106, DSMZ:ACC-12, DSMZCellDive:ACC-12, ECACC:96090515, EGA:EGAS00001000978, GDSC:907269, GEO:GSM115805, GEO:GSM629492, GEO:GSM629493, GEO:GSM887190, GEO:GSM888263, GEO:GSM907524, GEO:GSM1266783, GEO:GSM1266784, GEO:GSM1374581, GEO:GSM1669967, GEO:GSM2322620, GEO:GSM3150248, IARC_TP53:21422, LiGeA:CCLE_045, LINCS_LDP:LCL-1099, Lonza:1399, PharmacDB:JVM2_715_2019, PRIDE:PXD012087, PRIDE:PXD030304, Progenetix:CVCL_1319, PubChem_Cell_line:CVCL_1319, Wikidata:Q54899192

ID: CVCL_1319

Record Creation Time: 20220427T220653+0000

Record Last Update: 20260905T180919+0000

Ratings and Alerts

No rating or validation information has been found for JVM-2.

No alerts have been found for JVM-2.

Data and Source Information

Source: [Cellosaurus](#)

Usage and Citation Metrics

We found 6 mentions in open access literature.

Listed below are recent publications. The full list is available at [dkNET](#) .

Chen Z, et al. (2025) YTHDF2 promotes ATP synthesis and immune evasion in B cell malignancies. *Cell*, 188(2), 331.

Johnson Z, et al. (2023) IOA-244 is a Non-ATP-competitive, Highly Selective, Tolerable PI3K Delta Inhibitor That Targets Solid Tumors and Breaks Immune Tolerance. *Cancer research communications*, 3(4), 576.

Wu JL, et al. (2022) Phosphoproteomics Reveals the Role of Constitutive KAP1 Phosphorylation by B-cell Receptor Signaling in Chronic Lymphocytic Leukemia. *Molecular cancer research : MCR*, 20(8), 1222.

Roider T, et al. (2021) The impact of SAMHD1 expression and mutation status in mantle cell lymphoma: An analysis of the MCL Younger and Elderly trial. *International journal of cancer*, 148(1), 150.

Portelinha A, et al. (2021) ASN007 is a selective ERK1/2 inhibitor with preferential activity against RAS-and RAF-mutant tumors. *Cell reports. Medicine*, 2(7), 100350.

Maes T, et al. (2018) ORY-1001, a Potent and Selective Covalent KDM1A Inhibitor, for the Treatment of Acute Leukemia. *Cancer cell*, 33(3), 495.